Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JTM201 · 1 trial · 1 indication
Treatment-emergent AEs (TEAEs) from Baseline through end of followup
Serious AEs (SAEs) from the screening period through end of follow-up
| Arm | Type | Description |
|---|---|---|
| JTM201 | EXPERIMENTAL | Botulinum toxin |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| JTM201 | BIOLOGICAL | JTM201 20U in 0.5mL : JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location |
| Placebo | BIOLOGICAL | Placebo 20U in 0.5mL : Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location |
Inclusion Criteria: * Subjects ≥18 years of age based on the date of the written informed consent form. * Subject is able to provide written informed consent and comply with study procedures. * Subject has moderate or severe glabellar lines on maximum frown as assessed by the investigator and subje...
JTM201 is an investigational monoclonal antibody being developed for the treatment of moderate or severe glabellar lines, the vertical wrinkles between the eyebrows. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
JTM201 is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker BWAY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational treatment for glabellar lines.
JTM201 is in Phase 2 clinical development. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy for treating moderate or severe glabellar lines. The drug is investigational and has not received regulatory approval.
JTM201 has one completed Phase 2 clinical trial registered as NCT06246552, titled "Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines." The trial enrolled 480 participants in the United States and was randomized, double-blind, and placebo-controlled.
JTM201 is a monoclonal antibody, a type of biologic drug designed to bind to a specific target in the body. However, the specific molecular target of JTM201 has not been disclosed in available clinical trial information.